Apivar 500 mg Bee-hive strips for honey bees

Maa: Irlanti

Kieli: englanti

Lähde: HPRA (Health Products Regulatory Authority)

Aktiivinen ainesosa:

Amitraz

Saatavilla:

Veto Pharma

ATC-koodi:

QP53AD01

INN (Kansainvälinen yleisnimi):

Amitraz

Annos:

500 milligram(s)

Lääkemuoto:

Bee-hive strip

Prescription tyyppi:

LM: Licensed Merchant as defined in relevant national legislation

Terapeuttinen ryhmä:

Honey bees

Terapeuttinen alue:

amitraz

Käyttöaiheet:

Ectoparasiticide

Valtuutuksen tilan:

Authorised

Valtuutus päivämäärä:

2017-09-26

Valmisteyhteenveto

Health Products Regulatory Authority
26 September 2017
CRN000V9M
Page 1 of 6
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Apivar 500 mg Bee-hive strips for honey bees
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 15g strip contains:
ACTIVE SUBSTANCE:
Amitraz ……………………………………. 500 mg
Excipients:
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Bee-hive strips.
Rectangular translucent homogeneous rigid strip with a V-shape cutting
at one end
and a hole above. Strips are attached by two with a pre-cut line.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Honey bees.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Treatment of varroosis due to _Varroa destructor _sensitive to amitraz
in honey bees.
4.3 CONTRAINDICATIONS
Do not use in case of known resistance to amitraz.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
It is recommended not to use the product during the honey flow but
after the honey
harvest. See section Amount to be administered and administration
route.
Do not cut the strips.
Treat all colonies in an apiary simultaneously.
Do not re-use the strips.
The safety and efficacy of the product has only been investigated in
hives with a
single brood chamber (dose of 2 strips per hive/brood chamber). Use in
hives with
more than one brood chamber is not recommended.
Health Products Regulatory Authority
26 September 2017
CRN000V9M
Page 2 of 6
4.5 SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
Do not exceed or reduce the recommended dose and recommended duration
of use.
Remove the strips at the end of treatment.
The product should be part of an integrated varroa control programme
and
treatment rotations should be applied.
Bee colonies should be monitored routinely for the level of varroa
mite infestation in
order to inform what, and when, control methods should be used.
Inappropriate use of the product could result in increased risk of
resistance
development and could ultimately result in ineffective therapy.
The success of treatment should be mo